Systemic Sclerosis (Scleroderma): Epidemiology Forecasting Intelligence

February 2019 | 50 pages | ID: S1E98630CFCEN
CmaxInsight Market Intelligence

Abstracts

CmaxInsight’s “Systemic Sclerosis (Scleroderma)-Epidemiology Forecasting Intelligence” report provides a comprehensive analysis of the Systemic Sclerosis (Scleroderma) epidemiology, providing the historical, current, and forecasted data for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan during the period from 2018-2028.

Our epidemiology services include:

• Incidence and prevalence
• Diagnosis rate, treatment rate and mortality patterns
• Epidemiology-based forecasting and disease trends
• Size of different patient segments in a disease area
• Population based: disease occurrence, co-morbidities and treatment patterns
• Geographic - Regional - Ethnic differences

Along with the epidemiological data, the report also includes:

• Disease overview, causes, symptoms, classification, risk factor, pathophysiology, diagnosis and treatment
• Patient treatment journey
• Treatment algorithm and guidelines
• Assesses the disease risk and burden
• Highlights the unmet needs
• Market driver and barrier
• Growth opportunities and market trend analysis

Methodology

• This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Epidemiology Forecast model analysis by a team of industry experts.
• To generate accurate patient population estimates, utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies.
• All of the sources used to generate the data and analysis have been identified in the report.

Note: Systematic review of the epidemiological literature is also provided for full transparency into research and methods. This report can be delivered to the clients within 4-5 business days.

Contents

1. REPORT INTRODUCTION

2. SYSTEMIC SCLEROSIS (SCLERODERMA) EPIDEMIOLOGY OVERVIEW AT A GLANCE

3. MARKET SHARE DISTRIBUTION OF SYSTEMIC SCLEROSIS (SCLERODERMA)

4. DISEASE BACKGROUND AND OVERVIEW: SYSTEMIC SCLEROSIS (SCLERODERMA)

4.1. Introduction
4.2. Signs and Symptoms
4.3. Etiology
4.4. Risk Factors
4.5. Pathophysiology
4.6. Diagnostic Landscape
  4.6.1. Diagnostic Practices
  4.6.2. Diagnostic Criteria
  4.6.3. Diagnostic Recommendations
4.7. Treatment Landscape
  4.7.1. Current Treatment Practices
  4.7.2. Treatment Algorithm
  4.7.3. Treatment Recommendations

5. SYSTEMIC SCLEROSIS (SCLERODERMA) EPIDEMIOLOGY

5.1. Key Findings
5.2. Assumptions & Rationale
5.3. 7MM Epidemiology

6. EPIDEMIOLOGY OF SYSTEMIC SCLEROSIS (SCLERODERMA) BY COUNTRIES

7. UNITED STATES

7.1. Assumptions and Rationale
7.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
7.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
7.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
7.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
7.6. Treated Cases of Systemic Sclerosis (Scleroderma)

8. EU5

8.1. Germany
  8.1.1. Assumptions and Rationale
  8.1.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
  8.1.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
  8.1.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
  8.1.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
  8.1.6. Treated Cases of Systemic Sclerosis (Scleroderma)
8.2. France
  8.2.1. Assumptions and Rationale
  8.2.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
  8.2.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
  8.2.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
  8.2.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
  8.2.6. Treated Cases of Systemic Sclerosis (Scleroderma)
8.3. United Kingdom
  8.3.1. Assumptions and Rationale
  8.3.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
  8.3.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
  8.3.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
  8.3.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
  8.3.6. Treated Cases of Systemic Sclerosis (Scleroderma)
8.4. Spain
  8.4.1. Assumptions and Rationale
  8.4.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
  8.4.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
  8.4.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
  8.4.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
  8.4.6. Treated Cases of Systemic Sclerosis (Scleroderma)
8.5. Italy
  8.5.1. Assumptions and Rationale
  8.5.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
  8.5.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
  8.5.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
  8.5.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
  8.5.6. Treated Cases of Systemic Sclerosis (Scleroderma)

9. JAPAN

9.1. Assumptions and Rationale
9.2. Prevalent/Incident Cases of Systemic Sclerosis (Scleroderma)
9.3. Sub-Type Specific cases of Systemic Sclerosis (Scleroderma)*
9.4. Sex- Specific Cases of Systemic Sclerosis (Scleroderma)*
9.5. Diagnosed Cases of Systemic Sclerosis (Scleroderma)
9.6. Treated Cases of Systemic Sclerosis (Scleroderma)

10. UNMET NEEDS

Appendix
Report Methodology
Sources Used
Disclaimer
About CmaxInsight
*Indication Specific
Note: Certain sections of the table of contents would vary according to the availability of information.

List Of Tables

LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM
Table 2: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in United States
Table 4: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in United States*
Table 5: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in United States*
Table 6: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in United States
Table 7: Treated Cases of the Systemic Sclerosis (Scleroderma) in United States
Table 8: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Germany
Table 9: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany*
Table 10: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany*
Table 11: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Germany
Table 12: Treated Cases of the Systemic Sclerosis (Scleroderma) in Germany
Table 13: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in France
Table 14: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in France*
Table 15: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in France*
Table 16: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in France
Table 17: Treated Cases of the Systemic Sclerosis (Scleroderma) in France
Table 18: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Italy
Table 19: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy*
Table 20: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy*
Table 21: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Italy
Table 22: Treated Cases of the Systemic Sclerosis (Scleroderma) in Italy
Table 23: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Spain
Table 24: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain*
Table 25: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain*
Table 26: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Spain
Table 27: Treated Cases of the Systemic Sclerosis (Scleroderma) in Spain
Table 28: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in UK
Table 29: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in UK*
Table 30: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in UK*
Table 31: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in UK
Table 32: Treated Cases of the Systemic Sclerosis (Scleroderma) in UK
Table 33: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Japan
Table 34: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan*
Table 35: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan*
Table 36: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Japan
Table 37: Treated Cases of the Systemic Sclerosis (Scleroderma) in Japan

*Indication Specific

List Of Figures

LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in United States
Figure 4: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in United States*
Figure 5: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in United States*
Figure 6: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in United States
Figure 7: Treated Cases of the Systemic Sclerosis (Scleroderma) in United States
Figure 8: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Germany
Figure 9: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany*
Figure 10: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Germany*
Figure 11: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Germany
Figure 12: Treated Cases of the Systemic Sclerosis (Scleroderma) in Germany
Figure 13: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in France
Figure 14: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in France*
Figure 15: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in France*
Figure 16: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in France
Figure 17: Treated Cases of the Systemic Sclerosis (Scleroderma) in United France
Figure 18: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Italy
Figure 19: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy*
Figure 20: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Italy*
Figure 21: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Italy
Figure 22: Treated Cases of the Systemic Sclerosis (Scleroderma) in Italy
Figure 23: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Spain
Figure 24: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain*
Figure 25: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Spain*
Figure 26: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Spain
Figure 27: Treated Cases of the Systemic Sclerosis (Scleroderma) in Spain
Figure 28: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in UK
Figure 29: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in UK*
Figure 30: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in UK*
Figure 31: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in UK
Figure 32: Treated Cases of the Systemic Sclerosis (Scleroderma) in UK
Figure 33: Prevalent/Incident Cases of the Systemic Sclerosis (Scleroderma) in Japan
Figure 34: Sub-Type Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan*
Figure 35: Sex- Specific Cases of the Systemic Sclerosis (Scleroderma) in Japan*
Figure 36: Diagnosed Cases of the Systemic Sclerosis (Scleroderma) in Japan
Figure 37: Treated Cases of the Systemic Sclerosis (Scleroderma) in Japan

*Indication Specific